Qure Ai

Artificial Intelligence-driven algorithm for chest X-rays

CURRENT IMPACT

As on August 2023

50+

hospitals equipped with qXR software

80,000+

scans completed at different hospitals

Geographical Focus
  • PAN India
Potential Impact
  • Interpret

    62,500

    chest scans across

    50

    health sites

Samridh support

The financial assistance from SAMRIDH has enabled Qure.ai to raise commercial capital in the form of equity and debt for further expansion of qXR. Through this support, Qure AI has been able to provide free qXR licenses to assist in screening for radiological signs of COVID-19 and Tuberculosis on the chest X-rays, across 46 sites in India. The public health attention received through this effort has led Qure.ai to get a commercial opportunity with PATH under its UNITAID funded project in Maharashtra. In addition, it has been able to raise $40 million from healthcare investors, which will accelerate its global market expansion and support new product development for critical care and community diagnostics. SAMRIDH is also supporting Qure AI with business advisory services for market positioning, listing on Government e-Marketplace (GeM) portal, and market access through cross-linkages with other SAMRIDH supported entities which has resulted in successful deployment of qXR software at the GNRC Hospitals in Assam.

49%

Of COVID-19 tests in India are rapid antigen tests [1]

3,147

CB-NAAT machines available in India to detect lung diseases like Tuberculosis [2]

Large scale testing and tracking of diseases is crucial for deploying an effective public health response to combat highly infectious diseases like Tuberculosis (TB) and COVID-19. Rapid antigen tests and X-ray solutions can help detect these infections and produce quick results. However, India faced a severe shortage of testing supplies and medical devices during the COVID-19 pandemic. This adversely impacted the ability of hospitals and health workers in low-resource settings to monitor and extend timely and appropriate treatment to patients. With the increase in India’s respiratory burden post-COVID, access to testing and diagnostic supplies remains inaccessible to underserved areas and communities.

[1] Cherian P, Krishna S, Menon GI. Optimizing testing for COVID-19 in India.

[2] India TB Report 2021

qXR Software

 

qXR, is an AI-enabled chest X-ray solution by Qure.ai, that can identify up to 30 distinct lung abnormalities in under a minute. The qXR solution can be used by healthcare workers to identify, prioritize, and reduce the transmission of highly communicable diseases. Qure.ai is utilizing qXR to identify findings related to COVID-19 infections and use it as a triage tool in settings with limited diagnostic resources. This will help in prioritizing treatments for patients in low-resource settings based on individual patients’ need for urgent treatments.

Resources